Lisinopril
Qbrelis, Zestoretic, Zestril (lisinopril) is a small molecule pharmaceutical. Lisinopril was first approved as Prinivil on 1987-12-29. It is used to treat diabetic nephropathies, heart failure, hypertension, left ventricular dysfunction, and myocardial infarction in the USA. The pharmaceutical is active against angiotensin-converting enzyme.
Download report
Favorite
Top Prescription Drugs
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
---|---|
urogenital diseases | D000091642 |
cardiovascular diseases | D002318 |
endocrine system diseases | D004700 |
signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
Qbrelis, Zestril (generic drugs available since 2002-07-01, discontinued: Prinivil)
CombinationsZestoretic (generic drugs available since 2002-07-01, discontinued: Prinzide)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Hydrochlorothiazide
+
Lisinopril
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
ZESTORETIC | Almatica Pharma | N-019888 RX | 1989-07-20 | 3 products, RLD, RS |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
---|---|---|
lisinopril | ANDA | 2023-06-13 |
qbrelis | New Drug Application | 2020-03-31 |
zestoretic | New Drug Application | 2021-07-01 |
zestril | New Drug Application | 2020-06-22 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
diabetic nephropathies | EFO_0000401 | D003928 | — |
heart failure | EFO_0003144 | D006333 | I50 |
hypertension | EFO_0000537 | D006973 | I10 |
left ventricular dysfunction | — | D018487 | — |
myocardial infarction | EFO_0000612 | D009203 | I21 |
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Lisinopril, Qbrelis, Azurity | |||
9463183 | 2035-11-06 | DP | |
9616096 | 2035-11-06 | U-3, U-8, U-71, U-185, U-1723, U-1864, U-1991 | |
9814751 | 2035-11-06 | DP | |
10039800 | 2035-11-06 | U-3, U-8, U-71, U-185, U-1723, U-1864, U-1991 | |
10265370 | 2035-11-06 | DP | |
10406199 | 2035-11-06 | U-3, U-8, U-71, U-185, U-1723, U-1864, U-1991 | |
10940177 | 2035-11-06 | DP | |
11179434 | 2035-11-06 | DP |
ATC Codes
C: Cardiovascular system drugs
— C09: Agents acting on the renin-angiotensin system
— C09A: Ace inhibitors, plain
— C09AA: Ace inhibitors, plain
— C09AA03: Lisinopril
— C09B: Ace inhibitors, combinations
— C09BA: Ace inhibitors and diuretics
— C09BA03: Lisinopril and diuretics
— C09BB: Ace inhibitors and calcium channel blockers
— C09BB03: Lisinopril and amlodipine
— C10: Lipid modifying agents
— C10B: Lipid modifying agents, combinations
— C10BX: Lipid modifying agents in combination with other drugs
— C10BX07: Rosuvastatin, amlodipine and lisinopril
HCPCS
No data
Clinical
Clinical Trials
99 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hypertension | D006973 | EFO_0000537 | I10 | 8 | 3 | 6 | 11 | 7 | 35 |
Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 2 | — | 1 | 1 | 1 | 5 |
Heart failure | D006333 | EFO_0003144 | I50 | — | — | 3 | 1 | 1 | 5 |
Diabetic nephropathies | D003928 | EFO_0000401 | — | — | 1 | 3 | 1 | 5 | |
Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | 1 | 1 | 1 | 2 | 5 |
Chronic renal insufficiency | D051436 | N18 | — | 1 | 1 | 1 | — | 3 | |
Coronary artery disease | D003324 | I25.1 | — | — | — | 1 | — | 1 | |
Left ventricular dysfunction | D018487 | — | — | — | 1 | — | 1 | ||
Proteinuria | D011507 | HP_0000093 | R80 | — | — | — | 1 | — | 1 |
Systolic heart failure | D054143 | EFO_1001207 | I50.20 | — | — | — | 1 | — | 1 |
Show 4 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Duchenne muscular dystrophy | D020388 | — | 1 | 1 | — | 1 | 2 | ||
Polycystic kidney diseases | D007690 | Q61.3 | — | — | 2 | — | — | 2 | |
Kidney diseases | D007674 | EFO_0003086 | N08 | — | 1 | 1 | — | — | 2 |
Myocardial infarction | D009203 | EFO_0000612 | I21 | — | — | 1 | — | 1 | 2 |
Coronary disease | D003327 | — | — | 1 | — | 1 | 2 | ||
Heart diseases | D006331 | EFO_0003777 | I51.9 | — | — | 1 | — | 1 | 2 |
Left ventricular hypertrophy | D017379 | EFO_0003896 | — | — | 2 | — | — | 2 | |
Hypercholesterolemia | D006937 | HP_0003124 | — | — | 1 | — | — | 1 | |
Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | — | 1 | — | — | 1 |
Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | — | 1 | — | — | 1 |
Show 4 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Cognitive dysfunction | D060825 | G31.84 | — | 2 | — | — | — | 2 | |
Essential hypertension | D000075222 | I10 | — | 1 | — | — | 1 | 2 | |
Neoplasms | D009369 | C80 | — | 1 | — | — | — | 1 | |
Focal segmental glomerulosclerosis | D005923 | EFO_0004236 | — | 1 | — | — | — | 1 | |
Aging | D000375 | GO_0007568 | R41.81 | — | 1 | — | — | — | 1 |
Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 1 | — | — | — | 1 |
Cardiotoxicity | D066126 | EFO_1001482 | — | 1 | — | — | — | 1 | |
Lymphoma | D008223 | C85.9 | — | 1 | — | — | — | 1 | |
Oligospermia | D009845 | N46.1 | — | 1 | — | — | — | 1 | |
Prehypertension | D058246 | 1 | 1 | — | — | — | 1 |
Show 9 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | 5 | — | — | — | 1 | 6 | ||
Therapeutic equivalency | D013810 | 3 | — | — | — | — | 3 | ||
Fasting | D005215 | EFO_0002756 | 2 | — | — | — | — | 2 | |
Gastroparesis | D018589 | EFO_1000948 | K31.84 | 1 | — | — | — | — | 1 |
Stroke | D020521 | EFO_0000712 | I63.9 | 1 | — | — | — | — | 1 |
Prostatic neoplasms | D011471 | C61 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | — | — | — | — | 2 | 2 |
Cardiomyopathies | D009202 | EFO_0000318 | I42 | — | — | — | — | 1 | 1 |
Chest pain | D002637 | HP_0100749 | R07.9 | — | — | — | — | 1 | 1 |
Hyperparathyroidism | D006961 | EFO_0008506 | E21.3 | — | — | — | — | 1 | 1 |
Diastolic heart failure | D054144 | EFO_1000899 | I50.30 | — | — | — | — | 1 | 1 |
Diabetes complications | D048909 | — | — | — | — | 1 | 1 | ||
Diabetic retinopathy | D003930 | EFO_0003770 | — | — | — | — | 1 | 1 | |
Eye diseases | D005128 | EFO_0003966 | H44 | — | — | — | — | 1 | 1 |
Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | — | — | — | — | 1 | 1 |
Hiv infections | D015658 | EFO_0000764 | B20 | — | — | — | — | 1 | 1 |
Show 1 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | LISINOPRIL |
INN | lisinopril |
Description | Lisinopril is a dipeptide. It has a role as an EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor. It contains a L-prolino group and a L-lysine residue. |
Classification | Small molecule |
Drug class | antihypertensives (ACE inhibitors) |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | NCCCC[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O.O.O |
Identifiers
PDB | — |
CAS-ID | 76547-98-3 |
RxCUI | 1546022 |
ChEMBL ID | CHEMBL419213 |
ChEBI ID | 6503 |
PubChem CID | 5362119 |
DrugBank | DB00722 |
UNII ID | 7Q3P4BS2FD (ChemIDplus, GSRS) |
Target
Agency Approved
ACE
ACE
Organism
Homo sapiens
Gene name
ACE
Gene synonyms
DCP, DCP1
NCBI Gene ID
Protein name
angiotensin-converting enzyme
Protein synonyms
angiotensin I converting enzyme (peptidyl-dipeptidase A) 1, carboxycathepsin, CD143, CD143 antigen, dipeptidyl carboxypeptidase 1, Dipeptidyl carboxypeptidase I, Kininase II, peptidase P
Uniprot ID
Mouse ortholog
Ace (11421)
angiotensin-converting enzyme (P09470)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 11,180 documents
View more details
Safety
Black-box Warning
Black-box warning for: Lisinopril, Qbrelis, Zestoretic, Zestril
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
58,504 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more